Top

Published in:

01-11-2021 | Hyperparathyroidism | Original Article

Head-to-head comparison among ¹⁸F-choline PET/CT, 4D contrast-enhanced CT, and ¹⁸F-choline PET/4D contrast-enhanced CT in the detection of hyperfunctioning parathyroid glands: a systematic review and meta-analysis

Authors: Arnoldo Piccardo, Gianluca Bottoni, Luis Alejandro Boccalatte, Chiara Camponovo, Martina Musumeci, Lorenzo Bacigalupo, Carlos Collaud, Martina Ugolini, Francesco Fiz, Pierpaolo Trimboli

Published in: Endocrine | Issue 2/2021

Abstract

Introduction

In primary hyperparathyroidism (PHPT), the localization of hyperfunctioning parathyroid gland (HPTG) allows tailored surgery. Although Four-Dimensional Contrast-enhanced Computed Tomography (4DCeCT) and ¹⁸F-choline Positron Emission Tomography/Computed Tomography (PET/CT) are reported to be promising second-line imaging procedures, no meta-analysis of their comparison exists.

Design

we conducted a systematic review and meta-analysis to find original papers reporting the head-to-head comparison of 4DCeCT, ¹⁸F-choline PET/CT and integrated ¹⁸F-choline-PET/4DCeCT.

Methods

this systematic review was conducted according to PRISMA. PubMed, CENTRAL, Scopus, and Web of Science were searched until January 2021. Studies comparing the ability of 4DCeCT, ¹⁸F-choline PET/CT and ¹⁸F-choline PET/4DCeCT to identify HPTG in patients with PHPT were selected. A per patient-based analysis of the three procedures was conducted in all patients (detection rate, DR) and in those with histologically confirmed HPTG (sensitivity).

Results

Of the 78 records identified, five articles (153 PHPT patients) published between January the 1st, 2018 and January the 31st, 2021 were included. The pooled DR of ¹⁸F-choline PET/CT, 4DCeCT and ¹⁸F-choline PET/4DCeCT was 0.86, 0.69, and 0.86, respectively, while their pooled sensitivity was 0.89, 0.77 and 0.93, respectively. The analysis of pooled discrepancy showed that the sensitivity of ¹⁸F-choline PET/CT and ¹⁸F-choline PET/4DCeCT was higher than that of 4DCeCT by 0.11 and 0.13, respectively, the sensitivity of ¹⁸F-choline PET/4DCeCT being 0.06 higher than that of ¹⁸F-Choline PET/CT.

Conclusions

This meta-analysis suggests that the sensitivity of ¹⁸F-choline PET/CT and ¹⁸F-choline PET/4DCeCT is higher than that of 4DCeCT, while only a slight difference was observed between ¹⁸F-choline PET/CT and ¹⁸F-choline PET/4DCeCT.

S.J. Silverberg, Natural history of primary hyperparathyroidism. Endocrinol. Metab. Clin. North Am. 29, 451–64 (2000). https://doi.org/10.1016/s0889-8529(05)70145-6CrossRefPubMed

N.M. Singh Ospina, R. Rodriguez-Gutierrez, S. Maraka et al. Outcomes of parathyroidectomy in patients with primary hyperparathyroidism: a systematic review and meta-analysis. World J. Surg. 40, 2359–77 (2016). https://doi.org/10.1007/s00268-016-3514-1CrossRefPubMed

J.P. Bilezikian, M.L. Brandi, R. Eastell et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3561–9 (2014). https://doi.org/10.1210/jc.2014-1413CrossRefPubMedPubMedCentral

G. Noussios, P. Anagnostis, K. Natsis, Ectopic parathyroid glands and their anatomical, clinical and surgical implications. Exp. Clin. Endocrinol. Diabetes 120, 604–10 (2012). https://doi.org/10.1055/s-0032-1327628CrossRefPubMed

G. Treglia, R. Sadeghi, C. Schalin-Jäntti et al. Detection rate of (99m) Tc-MIBI single photon emission computed tomography (SPECT)/CT in preoperative planning for patients with primary hyperparathyroidism: A meta-analysis. Head. Neck 381, E2159–72 (2016). https://doi.org/10.1002/hed.24027CrossRef

C.Y. Lo, B.H. Lang, W.F. Chan et al. Prospective evaluation of preoperative localization by technetium-99m sestamibi scintigraphy and ultrasonography in primary hyperparathyroidism. Am. J. Surg. 193, 155–9 (2007). https://doi.org/10.1016/j.amjsurg.2006.04.020CrossRefPubMed

A. Harari, E. Mitmaker, R.H. Grogan et al. Primary hyperparathyroidism patients with positive preoperative sestamibi scan and negative ultrasound are more likely to have posteriorly located upper gland adenomas (PLUGs). Ann. Surg. Oncol. 18, 1717–22 (2011). https://doi.org/10.1245/s10434-010-1493-2CrossRefPubMedPubMedCentral

G. Treglia, P. Trimboli, M. Huellner et al. Imaging in primary hyperparathyroidism: focus on the evidence-based diagnostic performance of different methods. Minerva Endocrinol. 43, 133–143 (2018). https://doi.org/10.23736/S0391-1977.17.02685-2CrossRefPubMed

S. Minisola, C. Cipriani, D. Diacinti et al. Imaging of the parathyroid glands in primary hyperparathyroidism. Eur. J. Endocrinol. 174, D1–8 (2016). https://doi.org/10.1530/EJE-15-0565.CrossRefPubMed

10.

L.F. Starker, A. Mahajan, P. Björklund et al. 4D parathyroid CT as the initial localization study for patients with de novo primary hyperparathyroidism. Ann. Surgical Oncol. 18, 1723–8 (2011). https://doi.org/10.1245/s10434-010-1507-0CrossRef

11.

M. Mekel, R. Linder, B. Bishara et al. 4-dimensional computed tomography for localization of parathyroid adenoma. Harefuah 152, 710–712 (2013)PubMed

12.

M. Hamidi, M. Sullivan, G. Hunter et al. 4D-CT is superior to ultrasound and sestamibi for localizing recurrent parathyroid disease. Ann. Surg. Oncol. 25, 1403–1409 (2018). https://doi.org/10.1245/s10434-018-6367-zCrossRefPubMed

13.

Y. Tian, S.T. Tanny, P. Einsiedel et al. Four-dimensional computed tomography: clinical impact for patients with primary hyperparathyroidism. Ann. Surg. Oncol. 25, 117–121 (2018). https://doi.org/10.1245/s10434-017-6115-9CrossRefPubMed

14.

E. Quak, S. Lheureux, Y. Reznik et al. F18-choline, a novel PET tracer for parathyroid adenoma? J. Clin. Endocrinol. Metab. 98, 3111–2 (2013). https://doi.org/10.1210/jc.2013-2084CrossRefPubMed

15.

M. Hodolic, V. Huchet, S. Balogova et al. Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. Radio. Oncol. 48, 228–34 (2014). https://doi.org/10.2478/raon-2013-0075CrossRef

16.

T. Cazaentre, F. Clivaz, F. Triponez, False-positive result in 18F-fluorocholine PET/CT due to incidental and ectopic parathyroid hyperplasia. Clin. Nucl. Med 39, e328–30 (2014). https://doi.org/10.1097/RLU.0b013e3182a77b62CrossRefPubMed

17.

G. Treglia, E. Giovannini, D. Di Franco et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann. Nucl. Med. 26, 451–61 (2012). https://doi.org/10.1007/s12149-012-0602-7CrossRefPubMed

18.

L. Michaud, A. Burgess, V. Huchet et al. Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J. Clin. Endocrinol. Metab. 99, 4531–6 (2014). https://doi.org/10.1210/jc.2014-2821CrossRefPubMed

19.

M. Orevi, N. Freedman, E. Mishani et al. Localization of parathyroid adenoma by 11C-choline PET/CT: Preliminary results. Clin. Nucl. Med 39, 1033–8 (2014). https://doi.org/10.1097/RLU.0000000000000607CrossRefPubMed

20.

L. Lezaic, S. Rep, M.J. Sever et al. 18F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur. J. Nucl. Med. Mol. Imaging 41, 2083–9 (2014). https://doi.org/10.1007/s00259-014-2837-0CrossRefPubMed

21.

L. Michaud, S. Balogova, A. Burgess et al. A pilot comparison of 18f-fluorocholine PET/CT, ultrasonography and 123i/99mtc-sestamibi dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: Influence of thyroid anomalies. Med. (Baltim.) 94, e1701 (2015). https://doi.org/10.1097/MD.0000000000001701CrossRef

22.

G. Treglia, A. Piccardo, A. Imperiale et al. L. Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. Eur. J. Nucl. Med Mol. Imaging 46, 751–765 (2019). https://doi.org/10.1007/s00259-018-4123-zCrossRefPubMed

23.

E. Quak, D. Blanchard, B. Houdu et al. F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. Eur. J. Nucl. Med Mol. Imaging 45, 658–66 (2018). https://doi.org/10.1007/s00259-017-3911-1CrossRefPubMed

24.

Grimaldi S, Young J, Kamenicky P et al. Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of (18)F-Fluorocholine PET/CT. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-4018-z

25.

S.K. Taywade, N.A. Damle, A. Behera et al. Comparison of 18F-Fluorocholine positron emission tomography/computed tomography and four-dimensional computed tomography in the preoperative localization of parathyroid adenomas-initial results. Indian J. Endocrinol. Metab. 21, 399–403 (2017). https://doi.org/10.4103/ijem.IJEM_536_16CrossRefPubMedPubMedCentral

26.

W.P. Kluijfhout, J.D. Pasternak, J.E. Gosnell et al. (18)F Fluorocholine PET/MR imaging in patients with primary hyperparathyroidism and inconclusive conventional imaging: a prospective pilot study. Radiology 284, 460–467 (2017). https://doi.org/10.1148/radiol.2016160768.CrossRefPubMed

27.

A. Piccardo, P. Trimboli, M. Rutigliani et al. Additional value of integrated 18F-choline PET/4D contrast-enhanced CT in the localization of hyperfunctioning parathyroid glands and correlation with molecular profile. Eur. J. Nucl. Med Mol. Imaging 46, 766–775 (2019). https://doi.org/10.1007/s00259-018-4147-4CrossRefPubMed

28.

Giovanella L, Bacigalupo L, Treglia G et al. Will ¹⁸F-fluorocholine PET/CT replace other methods of preoperative parathyroid imaging? Endocrine. 2020 6. https://doi.org/10.1007/s12020-020-02487-y. Epub ahead of print.

29.

M.D.F. McInnes, D. Moher, B.D. Thombs et al. The PRISMA-DTA group. preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA 319, 388–396 (2018). https://doi.org/10.1001/jama.2017.19163CrossRefPubMed

30.

P.F. Whiting, A.W. Rutjes, M.E. Westwood et al. QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 155, 539–36 (2011). https://doi.org/10.7326/0003-4819-155-8-201110180-00009CrossRef

31.

R. Sadeghi, G. Treglia, Systematic reviews and meta-analyses of diagnostic studies: a practical guideline. Clin. Transl. Imaging 5, 83–87 (2017). https://doi.org/10.1007/s40336-016-0219-2CrossRef

32.

C. Amadou, G. Bera, M. Ezziane et al. 18F-fluorocholine PET/CT and parathyroid 4D computed tomography for primary hyperparathyroidism: the challenge of reoperative patients. World J. Surg. 43, 1232–1242 (2019). https://doi.org/10.1007/s00268-019-04910-6CrossRefPubMed

33.

I. Christakis, S. Khan, G.P. Sadler et al. ¹⁸Fluorocholine PET/CT scanning with arterial phase-enhanced CT is useful for persistent/recurrent primary hyperparathyroidism: first UK case series results. Ann. R. Coll. Surg. Engl. 101, 501–507 (2019). https://doi.org/10.1308/rcsann.2019.0059CrossRefPubMedPubMedCentral

34.

L.A. Boccalatte, N.L. Gómez, M. Musumeci et al. ¹⁸F-choline PET/4D CT in hyperparathyroidism: correlation between biochemical data and study parameters. Rev. Esp. Med Nucl. Imagen Mol. 39, 273–278 (2020). https://doi.org/10.1016/j.remn.2020.03.017CrossRefPubMed

35.

V. Pretet, M. Rotania, M. Helali et al. ¹⁸F-Fluorocholine PET and multiphase CT integrated in dual modality PET/4D-CT for preoperative evaluation of primary hyperparathyroidism. J. Clin. Med 9, 2005 (2020). https://doi.org/10.3390/jcm9062005. Jun 26CrossRefPubMedCentral

36.

L.A. Boccalatte, F. Higuera, N.L. Gómez et al. Usefulness of 18F-Fluorocholine positron emission tomography–computed tomography in locating lesions in hyperparathyroidism: a systematic review. JAMA Otolaryngol. Head. Neck Surg. 145, 743–750 (2019). https://doi.org/10.1001/jamaoto.2019.0574CrossRefPubMed

37.

38.

S. Fakhran, B.F. Branstetter, D.A. Pryma, Parathyroid imaging. Neuroimaging Clin. N. Am. 18, 537–549 (2008). https://doi.org/10.1016/j.nic.2008.03.006CrossRefPubMed

Title: Head-to-head comparison among 18F-choline PET/CT, 4D contrast-enhanced CT, and 18F-choline PET/4D contrast-enhanced CT in the detection of hyperfunctioning parathyroid glands: a systematic review and meta-analysis
Authors: Arnoldo Piccardo
Gianluca Bottoni
Luis Alejandro Boccalatte
Chiara Camponovo
Martina Musumeci
Lorenzo Bacigalupo
Carlos Collaud
Martina Ugolini
Francesco Fiz
Pierpaolo Trimboli
Publication date: 01-11-2021
Publisher: Springer US
Keyword: Hyperparathyroidism
Published in: Endocrine / Issue 2/2021
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-021-02798-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Design

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2021

Is local excision sufficient in selected grade 1 or 2 type III gastric neuroendocrine neoplasms?

Association of diabetes-related variants in ADCY5 and CDKAL1 with neonatal insulin, C-peptide, and birth weight

Antiphospholipid antibodies in patients with Graves’ orbitopathy: preliminary data

Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas

The association between triglyceride-glucose index and the incidence of type 2 diabetes mellitus—a systematic review and dose–response meta-analysis of cohort studies

Serum secreted frizzled-related protein 5 in relation to insulin sensitivity and its regulation by insulin and free fatty acids

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage